Volume 6 Supplement 3
Immunoregulatory role of secretory leukocyte protease inhibitor in allergic asthma
© Marino et al; licensee BioMed Central Ltd. 2010
Published: 26 November 2010
Asthma is a complex and multi-factorial inflammatory disease . It is one of the most common chronic diseases among children and adolescents . Secretory leukocyte protease inhibitor (SLPI) has shown higher levels in asthmatic patients and its function as an anti-inflammatory protein has been documented in respiratory diseases [3, 4]. However, its role in the immunomodulation of the response during allergic asthma has not yet been fully elucidated. The aim of this study was to evaluate the role of SLPI in the development of phenotypes associated with allergic asthma, and the effect of resiquimod treatment on the SLPI and the possible mechanisms of action involved in the disease.
Materials and methods
The importance of SLPI was assessed by evaluating airway resistance and inflammatory parameters in SLPI transgenic and knock-out mice using an ovalbumin (OVA)-induced model of acute allergic asthma and treatment with resiquimod.
Allergic SLPI transgenic mice showed a significant decrease in airway resistance compared to wild-type mice (6.3 ± 1.1 vs. 8.0 ± 2.1 cm H20 × s/ml, p < 0.001), the same effect was observed with inflammatory cell infiltration, eosinophil percentage (24 ± 1.1% vs. 29 ± 2.3%, p < 0.001), goblet cells (6 ± 1.4 vs. 36 ± 4.0%, p < 0.001) in the lungs and IgE levels (2014.1 ± 309.2 vs. 4173.2 ± 685.6 ng/ml, p < 0.001) in plasma. Allergic SLPI knock-out mice displayed significantly higher values compared to wild-type mice. They include lung resistance (8.6 ± 2.7 vs. 6.6 ± 0.5 cm H20*s/ml, p < 0.001), inflammatory cell influx, eosinophils (36.0 ± 2.7 vs. 29.0 ± 1.5%, p < 0.001), goblet cells (40 ± 4.1 vs. 30 ± 1.4%, p < 0.001), cytokine levels in the lungs (p < 0.05) and plasma IgE levels (3598 ± 204.7 vs. 2763 ± 220.3 ng/ml, p < 0.001). Expression of SLPI decreased inflammation in the lungs, plasma IgE levels, and lung resistance, whereas the ablation of SLPI has the opposite effect. Treatment with resiquimod improved airway resistance and inflammation of the lungs in SLPI knock-out and wild type, demonstrating that its effect is independent of the expression of SLPI.
SLPI plays an immunoregulatory role in the respiratory tract by reducing the inflammatory process and by improving lung physiology in a murine model of acute allergic asthma.
R. Marino and P. Camateros are both supported by a CIHR Doctoral Award. We acknowledge the histology expert assistance of Dr. Marie-Christine Guiot.
- Myers TR: Use of heliox in children. Respir Care. 2006, 51: 619-631.PubMedGoogle Scholar
- Blais L, Beauchesne MF, Levesque S: Socioeconomic status and medication prescription patterns in pediatric asthma in Canada. J Adolesc Health. 2006, 38: 607-616. 10.1016/j.jadohealth.2005.02.010.PubMedGoogle Scholar
- Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA, Shapiro SD, Elias JA: Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000, 192: 1587-1600. 10.1084/jem.192.11.1587.PubMed CentralPubMedView ArticleGoogle Scholar
- Weldon S, McGarry N, Taggart CC, McElvaney NG: The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses. Biochem Soc Trans. 2007, 35: 273-276. 10.1042/BST0350273.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd.